Congratulations on the approval of YESight Medical's first ultra-wide field scanning laser ophthalmoscope!

Recently, Yetsea 10, as known as the first ultra-wide field Scanning laser ophthalmoscope of YESight Medical, was approved by the National Class II Medical Device Registration Certificate. This means that the category of high-end ultra-wide field fundus laser imaging will usher in a new revolution.

As one of the first SLO devices to complete clinical trials in China, the Yetsea 10 has been clinically recognized by top ophthalmology hospitals in China, such as Beijing Tongren Hospital, Shenzhen People's Hospital and Guangzhou Aier Ophthalmology Hospital, and its performance indicators have reached or even surpassed those of imported products, providing doctors with a precise diagnostic basis for early detection of blinding eye diseases and continuous monitoring of the condition, thus significantly improving the clinical detection rate. The non-contact design combined with the safe laser light source ensures a low-risk, comfortable and harmless examination process, which enhances the patient's examination experience, demonstrates China's strength in medical science and technology innovation, and leads the innovation in the field of ophthalmic medical devices.

As an ultra-wide-field SLO device, this product can achieve 168° FOV in a single capture, featuring a wide field of view for fundus imaging, non-mydriasis, strong refractive media penetration, fast imaging speed, and clear images, providing unprecedented convenience and accuracy for fundus examination.

It is worth mentioning that this device adopts four-wavelength laser (R/G/B/IR) layered scanning imaging technology, which can fully cover the 10 layers of the retina, providing doctors with broader, more comprehensive, and deeper clinical information about the fundus.

Schematic diagram of four-wavelength laser stratified scanning

It is also the world's first ultra-wide-field confocal Scanning laser ophthalmoscope based on electronic scanning mirror technology developed by YESight Medical. The technology achieves a more compact body structure, and at the same time has a stronger scalability in performance. The core components are self-developed with a number of patented technologies and intellectual property rights, pioneering new technologies in the field of SLO imaging. The convenience of the product, which can be flexibly deployed to remote or inconveniently located areas, greatly broadens the accessibility of medical services, brings advanced ophthalmic diagnostic capabilities to primary healthcare organizations, and meets the needs of grassroots patients for high-quality ophthalmological examinations, creating a novel and highly efficient solution to eye health services.

Mr Wu Haizhou, Founder of YESight Medical, said with confidence:

“With its exquisite body design, Yetsea10 embodies the years of research and development wisdom and hard work of our team. Its successful approval is not only an affirmation of our efforts, but also an important milestone for YESight Medical to officially enter the domestic high-end ultra-wide field SLO market. We feel deeply proud, and we will provide Chinese ophthalmologists with more efficient and accurate diagnostic tools through independent innovative Chinese technology, jointly guarding the eye health of patients.”

In the future, YESight Medical is committed to comprehensively covering various ophthalmology specialties such as fundus, anterior segment, optic nerve, optometry and vision science, striving to cover more than 90% of domestic ophthalmology diagnostic needs. YESight Medical will continue to conduct research and development and innovate, enhance frontier technologies such as automation and AI, and strive to launch advanced ophthalmology medical equipment independently developed, making more significant contributions to the progress of ophthalmology medical undertakings in China and the well-being of public eye health. At the same time, it will actively embrace the trend of globalization, expand its layout in overseas markets, strengthen cooperation and exchanges with internationally renowned medical institutions, and aim to provide more precise and efficient diagnosis and treatment services for ophthalmic patients worldwide.